2015


To access this material please log in or register

Register Authorize
2015/№3

Clinical value of galectin-3 measurements in patients with CHF: Comparison with brain natriuretic peptide in diagnostics of chronic heart failure

Gyamdzhyan K. A., Maksimov M. L., Pavlova L. I.
State Budgetary Educational Institution of Higher Professional Education “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bldg. 2, Moscow 119991

Keywords: biomarkers, cardiovascular diseases, monitoring of treatment efficacy, disease prognosis, risk stratification

DOI: 10.18087/rhfj.2015.3.2034

The review focuses on the role of biomarkers in diagnostics of CHF. Two biomarkers, a clinically well established biomarker, brain natriuretic peptide (BNP), and a new biomarker for CHF, galectin-3, were compared for their diagnostic and prognostic value. The authors provided a review of data from major studies of biomarkers.
  1. Агеев Ф. Т., Арутюнов Г. П., Беленков Ю. Н., Васюк Ю. А., Мареев В. Ю., Мартыненко А. В., и др. Хроническая сердечная недостаточность. – Москва. ГЭОТАР-Медиа, 2010. – 336 с.
  2. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  3. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92 (6):843–849.
  4. Kim H.‑N., Januzzi J. L. Natriuretic Peptide Testing in Heart Failure. Circulation. 2011;123 (18):2015–2019.
  5. Maisel A. S., Krishnaswamy P., Nowak R. M., McCord J., Hollander J. E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002;347 (3):161–167.
  6. Januzzi J. L., Camargo C. A., Anwaruddin S., Baggish A. L., Chen A. A., Krauser D. G., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005;95 (8):948–954.
  7. Wieczorek S. J., Wu A. H. B., Christenson R., Krishnaswamy P., Gottlieb S., Rosano T., et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am. Heart J. 2002;144 (5):834–839.
  8. Maisel A. S., Peacock W. F., McMullin N., Jessie R., Fonarow G. C., Wynne J., et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J. Am. Coll. Cardiol. 2008;52 (7):534–540.
  9. Anand I. S., Fisher L. D., Chiang Y.‑T., Latini R., Masson S., Maggioni A. P., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107 (9):1278–1283.
  10. Mueller T., Gegenhuber A., Poelz W., Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005;91 (5):606–612.
  11. Mueller C., Scholer A., Laule-Kilian K., Martina B., Schindler C., Buser P., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 2004;350 (7):647–654.
  12. Knebel F., Schimke I., Pliet K., Schattke S., Martin S., Borges A. C., et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J. Card. Fail. 2005;11 (5 Suppl): S38 – S41.
  13. Cheng V., Kazanagra R., Garcia A., Lenert L., Krishnaswamy P., Gardetto N., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol. 2001;37 (2):386–391.
  14. Chandra K. S. Biomarker-guided therapy for heart failure. Indian Heart Journal. 2012;64 (2):178–181.
  15. Eurlings L. W. M., van Pol P. E. J., Kok W. E., van Wijk S., Lodewijks-van der Bolt C., Balk A. H. M. M., et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J. Am. Coll. Cardiol. 2010;56 (25):2090–2100.
  16. Januzzi J. L., Rehman S. U., Mohammed A. A., Bhardwaj A., Barajas L., Barajas J., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2011;58 (18):1881–1889.
  17. Драпкина О. М., Дуболазова Ю. В. Применение биологических маркеров в диагностике диастолической сердечной недостаточности. ЖСН. 2011;12 (6):364–372.
  18. Wang T. J., Larson M. G., Levy D., Benjamin E. J., Leip E. P., Wilson P. W. F., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109 (5):594–600.
  19. Das S. R. Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study. Circulation. 2005;112 (14):2163–2168.
  20. McCullough P. A., Duc P., Omland T., McCord J., Nowak R. M., Hollander J. E., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am. J. Kidney Dis. 2003;41 (3):571–579.
  21. Vanderheyden M., Bartunek J., Filippatos G., Goethals M., Vlem B. V., Maisel A. Cardiovascular disease in patients with chronic renal impairment: role of natriuretic peptides. Congest Heart Fail. 2008;14 (4 Suppl 1):38–42.
  22. Van Kimmenade R. R. J., Pinto Y. M., Januzzi J. L. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am. J. Cardiol. 2008;101 (3A): 39–42.
  23. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Research Reports in Clinical Cardiology. 2013;13.
  24. Kim H., Lee J., Hyun J. W., Park J. W., Joo H., Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol. Int. 2007;31 (7):655–662.
  25. Karlsson A., Christenson K., Matlak M., Björstad A., Brown K. L., Telemo E., et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology. 2009;19 (1):16–20.
  26. Van Kimmenade R. R., Januzzi J. L., Ellinor P. T., Sharma U. C., Bakker J. A., Low A. F., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 2006;48 (6):1217–1224.
  27. Lok D. J. A., Van Der Meer P., la Porte P. W. B.‑A. de, Lipsic E., Van Wijngaarden J., Hillege H. L., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99 (5):323–328.
  28. Lok D. J., Lok S. I., Bruggink-André de la Porte P. W., Badings E., Lipsic E., van Wijngaarden J., et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102 (2):103–110.
  29. De Boer R. A., Lok D. J. A., Jaarsma T., van der Meer P., Voors A. A., Hillege H. L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011;43 (1):60–68.
  30. Milting H., Ellinghaus P., Seewald M., Cakar H., Bohms B., Kassner A., et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung Transplant. 2008;27 (6):589–596.
  31. Sharma U. C., Pokharel S., van Brakel T. J., van Berlo J. H., Cleutjens J. P. M., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110 (19):3121–3128.
  32. Henderson N. C., Mackinnon A. C., Farnworth S. L., Poirier F., Russo F. P., Iredale J. P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 2006;103 (13):5060–5065.
  33. Liu Y.‑H., Ambrosio M. D’, Liao T. -d., Peng H., Rhaleb N.‑E., Sharma U., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion / growth-regulatory lectin. AJP: Heart and Circulatory Physiology. 2008;296 (2):H404 – H412.
Gyamdzhyan K. A., Maksimov M. L., Pavlova L. I. Clinical value of galectin-3 measurements in patients with CHF: Comparison with brain natriuretic peptide in diagnostics of chronic heart failure. Russian Heart Failure Journal. 2015;16 (3):187–192

To access this material please log in or register

Register Authorize
Ru En